ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
KRAS strikes back
First-in-human trial initiations reveal four KRAS assets.
ESMO 2024 – NiKang’s case for a better Welireg
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Astra takes Steap2 into human trials
First-in-human clinical trial listings include AZD0754, Astra’s internally developed Car-T therapy.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
